Video

Dr. Rampal on Symptoms of Disease Progression in Myelofibrosis

Raajit K. Rampal, MD, PhD, discusses symptoms of disease progression in myelofibrosis.

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses symptoms of disease progression in myelofibrosis.

No clear definition of disease progression exists in myelofibrosis, but certain factors can be indicative of progression, including patient-reported symptoms, Rampal explains. For example, a patient who had stable disease with JAK inhibitor therapy and begins reporting recurrence of initial symptoms or emergence of new symptoms could be experiencing symptomatic disease progression, Rampal explains.

Hematologic indicators of progression include decreased platelets or hemoglobin that require transfusion in a patient with previously transfusion-independent myelofibrosis receiving JAK inhibitors, says Rampal. The presence of increased circulating blasts is another indicator of progression to accelerated phase myelofibrosis or beyond, Rampal says. Finally, increased spleen or liver size, confirmed radiographically by scans, is consistent with disease progression in myelofibrosis, Rampal concludes.

Related Videos
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Binod Dhakal, MD
Sheldon M. Feldman, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.